ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMM Immupharma Plc

2.25
0.07 (3.21%)
Last Updated: 09:58:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 3.21% 2.25 2.16 2.40 2.25 2.20 2.20 618,502 09:58:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -3.81M -0.0114 -1.93 7.33M

Immupharma PLC AIM Rule 17 Notice (4650O)

18/08/2017 5:09pm

UK Regulatory


Immupharma (LSE:IMM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Immupharma Charts.

TIDMIMM

RNS Number : 4650O

Immupharma PLC

18 August 2017

18 August 2017

ImmuPharma Plc

AIM Rule 17 Notice

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends

 
 For further information please contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    Patrick Claridge, David Hignell, 
    Jamie Spotswood, Corporate Finance    +44 (0)20 3861 
    Rob Rees, Corporate Broking                6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKFDKABKDOFD

(END) Dow Jones Newswires

August 18, 2017 12:09 ET (16:09 GMT)

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Your Recent History

Delayed Upgrade Clock